Advaxis Engages the Numoda Corporation to Oversee Phase II Clinical Trials of ADXS11-001
Advaxis Completes Debt Financing
Advaxis Receives FDA Response to Orphan Drug Filing
Advaxis Develops Innovative Approach in Cancer Mechanism Targeting
More News
Advaxis is a biotechnology company that uses live genetically modified Listeria monocytogenes to treat cancers, infectious disease and problems of the immune system.